OxyContin Abuse Deterrent Formulation Voted Beneficial By FDA Panel, But Questions Remain

 
• By Brenda Sandburg
  
Pills
FDA advisory committee gives mixed reviews to OxyContin ADF postmarketing studies • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers